RSH, AVR, NTI: Best performing ASX healthcare equipment stocks in June

Follow us on Google News:
 RSH, AVR, NTI: Best performing ASX healthcare equipment stocks in June
Image source: © Sudok1 | Megapixl.com

Highlights

  • The S&P/ASX 200 Health Care closed on Monday with a gain of 1.25%.
  • The healthcare index has lost 1.55% over this month.
  • RSH, AVR, and NTI are three stocks from ASX healthcare that have outperformed the healthcare index and are up by more than 15% this month.

The S&P/ASX200 closed on Monday, gaining 127.30 points or 1.94% to 6,706.00. The index has gained 4.24% over the last five days but is down 9.92% on a year-to-date basis. Aligning with the ASX benchmark, the S&P/ASX 200 Healthcare also closed on Monday with a gain of 1.25%. The index is down 10.97% YTD and has lost 1.55% over this month.

Today, in this article we will look at three stocks from ASX healthcare - RSH, AVR, and NTI which have racked up over 15% gains this month and have outperformed the healthcare index.

Data source: Refinitiv as of 27 June 2022

Respiri Limited (ASX:RSH)

Respiri Limited is a medical technology company that assists respiratory health management. The company boasts a world-first technology that provides an objective measure of airway limitation by detecting wheeze, a typical symptom of asthma, Chronic Obstructive Pulmonary Disease (COPD) and other respiratory diseases.

Recently, Respiri appointed Brad Snow, a leading US med-tech executive, as a Non-Executive Director of the company. With proven success in leading emerging health technology companies, Mr Snow holds an in-depth experience in the US healthcare industry,

In the March 2022 quarter, the company was majorly focused on the US market with resource and investment strategies in place.

Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company, which is focused on developing next-generation technologies to provide life-changing outcomes for patients. The company’s lead product is Anteris’ DurAVR™ 3D, a single-piece aortic heart valve replacement.

Recently, the company reported encouraging results from its DurAVR™ in the first group of patients at the six-month mark. It was an informal follow-up in which DurAVR™ demonstrated continued excellent haemodynamics, resulting in a dramatic enhancement in patients’ ability to exercise, etc.

Neurotech International Limited (ASX: NTI)

Neurotech is conducting clinical studies to assess the anti-inflammatory, neuroprotective, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains. The company has submitted major provisional patents regarding the composition and usage of NTI164 for curing different types of neurological disorders.

Recently, Neurotech reported encouraging results from preclinical research. The study demonstrated significant anti-inflammatory synergistic action of NTI164, when coupled with Diclofenac at low doses.

Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) used in curing different pain and inflammatory conditions.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK